Innovest
Global: Winslow Asset Management Remains Long Shares of
IVST During Second Quarter 2018 -- Spotlight Growth
Sacramento, CA
-- August 09, 2018 -- InvestorsHub
NewsWire
--
Spotlight Growth has published new content on Innovest
Global, Inc.
(OTC
PINK: IVST). Innovest
Global, Inc.
is a diversified holding company that focuses on acquiring niche,
high-growth businesses that are capable of generating significant
annual revenue. The company's planned subsidiaries operate across
telehealth, biotech, commercial energy, business-to-business
distribution, national call center and auto
sales.
The
report provides an overview of Innovest
Global, Inc.,
its subsidiaries, financials, biotech industry analysis,
U.S./global cancer rates and more.
American
Cancer Society: Estimated 21.7 Million New Cancer Cases By
2030
Cancer
continues to be a major global healthcare issue, as millions of
people die each year from the illness. Most of us are familiar with
the pain and suffering that cancer can cause, which shows that
there is a desperate need for a modern treatment plan. For too long
the primary treatment for cancer has continued to be chemotherapy,
which itself can be extremely painful and cause other
complications.
According
to the U.S.
Centers for Disease Control (CDC),
cancer is the second leading cause of death within the United
States, behind heart disease. In the latest data available, the CDC
notes that 595,930 Americans died from cancer in
2015.
Unfortunately,
many health and science experts do not see an end in sight for
cancer. According to the American
Cancer Society (ACS),
there will be an estimated 1.74 million new cases of cancer that
are diagnosed in the United States alone this
year.
The
global trends are far more pessimistic. In 2012,
the ACS reported
that there were 14.1 million new cases in cancer resulting in 8.2
million deaths globally. By 2030, the ACS estimates that there will
be around 21.7 million new cases of cancer resulting in 13 million
deaths worldwide. However, the group does admit that "the future
burden will probably be even larger because of the adoption of
western lifestyles, such as smoking, poor diet, physical
inactivity, and few childbirths, in economically developing
countries," according to the report.
According
to Grand View
Research, the global
biotechnology market is forecast to reach $727.1 billion USD by
2025, which represents an annual growth rate of
7.40%.
IVST:
Completion of 20% Stake In
StemVax, Brain Cancer Vaccine Technology
Awarded U.S. Patent
Innovest
Global has
continued to impress through the halfway point of 2018. The
Cleveland, Ohio-based conglomerate has
managed to close and integrate five acquisitions into its two
operational divisions: Biotechnology & Health Sciences and
Commercial & Industrial. The management team continues to fire
on all cylinders, as Innovest
Global
reported three straight months of record profits through June
2018.
The
latest completed acquisition by Innovest
Global was the
20% stake in StemVax
Therapeutics,
a translational biotechnology company. StemVax
is
currently in the process of developing a cancer vaccine therapy to
treat again brain tumors, specifically Glioblastomas (the same form
of brain cancer as Arizona
Senator John McCain).
StemVax
Therapeutics'
flagship technology, the StemVax
Glioblast
(SVX-GB), is
described as "a cancer vaccine, which is a medication that
stimulates or restores the immune system's ability to fight an
existing cancer by strengthening the body's natural defenses
against the cancer cells. It is a meaningful technology, which
could significantly improve the quality of life and prognosis for
the many people who suffer from brain tumors," according to the
company's release.
Shortly
after Innovest
Global
announced the completion of
stake acquisition in StemVax
Therapeutics,
the biotechnology company announced that its cancer vaccine
technology has been awarded a U.S. Patent. Specifically, the patent
relates to "cancer antigens" and the "treatment of cancer using
vaccination therapy."
"Patent
approval is
the trigger for us to engage major health organizations, to
continue the progress toward the 'StemVax
Glioblast'
brain tumor vaccine going to market and improving people's lives.
After decades of research, it took nine years in the patent
process, and is a transformational achievement," said Dr. Dwain
Morris-Irvin, President of Innovest's
Biotech
Division. The patent application was initially filed back in 2008
by a hospital research organization, and was co-authored by Dr.
Morris-Irvin, who is also the StemVax
Chief Science
Officer, according to an Innovest
Global
corporate release.
On August 6,
2018, Innovest
Global made a
major announcement that it has signed an agreement with the
highly-respected Cedars-Sinai
Medical Center in
Los Angeles, CA. In the agreement, Innovest
has been
awarded an exclusive worldwide license "for all of the intellectual
property needed to commercialize the StemVax
Glioblast
brain tumor
vaccine," according to the press release. Cedars-Sinai Medical
Center is a non-profit hospital that is widely considered to be one
of the top hospitals and research organizations in the entire
world.
IVST: First Half
Accomplishments
Outside
of the successful acquisitions, Innovest
Global
reported second quarter sales growth of 55.80% compared to the
first quarter 2018 ($1.1 million in Q2 versus $708,804 in Q1).
Furthermore, Innovest
Global
reported current assets of $877,861 and cash holdings of $561,062.
Management notes that there continues to be no convertible debt,
warrants or options outstanding, as of end of second quarter
2018.
During
the first quarter, Innovest
Global
received its first institutional shareholder in Winslow
Asset Management. The
Ohio-based asset manager purchased 10,000 shares during the first
three months of 2018, according to a 13F filing. After an updated
filing for the second quarter, it is confirmed that Winslow Asset
Management continues to
be long
shares of
Innovest
Global.
Winslow stayed put during the second quarter, not adding or selling
their current position.
While
there were certainly some enticing entry points that Winslow Asset
Management could have used to engage in dollar-cost averaging
during the second quarter, it is certainly a vote of confidence
that the fund is remaining a bullish stance on Innovest.
Here is a
complete list from a recent Innovest
Global press
release, which thoroughly highlighting the
impressive achievements through
the first half of 2018:
- Sales are up 55.8%. ($1,104,367 in Q2 compared to $708,804
in Q1). June Sales were highest ever, at 16.8% higher than May, the
previous record.
- End Q2 current assets of $877,861 include cash on hand of
$561,062.
- Our capital structure includes an unchanged free-trading
float of 11,796,710 common shares. There are no convertible debts,
no warrants or options outstanding.
- Our headcount is 44 employees, up from 26 at the start of
the quarter.
- Our stock price is up 725% as of this past Friday, since
our January 2, 2018 close. Since Thursday of last week IVST saw
more than double average trading volume, following the
StemVax announcement.
- We received notice that Winslow Asset Management registered
as a shareholder, marking our first institutional shareholder
position.
- We closed several key contracts with organizations ranging
from local governments, to the United States Navy, University
Hospitals, Cleveland Indians, University of Louisiana, Iowa
Department of Transportation, Houston Metro, Tarkette
and a $650K exclusive contact from Byram Healthcare, a division
of a Fortune 500 Company.
- We've got a world-class team including two independent
members of our Board of Directors, and our key corporate leadership
is highlighted on our new corporate
website.
For more
information on Innovest
Global,
Inc., please
visit http://innovestglobal.com and http://spotlightgrowth.com/index.php/2018/08/06/this-undervalued-gem-has-a-patented-technology-for-treating-cancer-with-vaccination-therapy/
SpotlightGrowth.com is
a digital hub for micro-caps, small-caps, crowdfunding,
cryptocurrency, and other emerging growth
investors. SpotlightGrowth.com serves
as our media subsidiary and provides insights on small cap
companies.
Disclaimer:
Spotlight
Growth is compensated, either directly or via a third party, to
provide investor relations services for its
clients. Spotlight
Growth creates exposure for companies through a customized
marketing strategy, including design of promotional material, the
drafting and editing of press releases and media
placement.
All
information on featured companies is provided by the companies
profiled, or is available from public sources. Spotlight Growth and
its employees are not a Registered Investment Advisor, Broker
Dealer or a member of any association for other research providers
in any jurisdiction whatsoever and we are not qualified to give
financial advice. The information contained herein is based on
external sources that Spotlight Growth believes to be reliable, but
its accuracy is not guaranteed. Spotlight
Growth may create reports and content that has been compensated by
a company or third-parties, or for purposes of self-marketing.
Spotlight Growth was compensated two thousand five hundred dollars
cash and fifty thousand restricted shares for the creation and
dissemination of this content.
This
material does not represent an investment solicitation. Certain
statements contained herein constitute "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Such statements may include, without limitation,
statements with respect to the Company's plans and objectives,
projections, expectations and intentions. These forward-looking
statements are based on current expectations, estimates and
projections about the Company's industry, management's beliefs and
certain assumptions made by management.
The
above communication, the attachments and external Internet links
provided are intended for informational purposes only and are not
to be interpreted by the recipient as a solicitation to participate
in securities offerings.
Investments
referenced may not be suitable for all investors and may not be
permissible in certain jurisdictions.
Spotlight
Growth and its affiliates, officers, directors, and employees may
have bought or sold or may buy or sell shares in the companies
discussed herein, which may be acquired prior, during or after the
publication of these marketing materials. Spotlight
Growth, its
affiliates, officers, directors, and employees may sell the stock
of said companies at any time and may profit in the event those
shares rise in value. For more information on our disclosures,
please visit: http://spotlightgrowth.com/index.php/disclosures/
Contact
Information:
Derek C.
McCarthy
Strategy
Consultant
Investors.news@yahoo.com
